Validation of two new scales for the assessment of fatigue in Multiple Sclerosis: F-2-MS and FACIT-F.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 03 03 2022
revised: 08 04 2022
accepted: 21 04 2022
pubmed: 30 4 2022
medline: 29 6 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

Fatigue is one of the most common symptoms in neurology, especially in MS patients with a prevalence of 65%. It is described as the most disabling symptom by 40% of MS patients. This study aimed to validate the Functional Assessment of Chronic Illness Therapy fatigue version (FACIT-F) and the F-2-MS scale, a new tool to distinguish between fatigue and fatigability. One hundred and fifteen patients with relapsing-remitting MS were enrolled. All patients completed a comprehensive neuropsychological battery, previously validated in MS. Fatigue was evaluated using the Fatigue Severity Scale (FSS), the Modified version of the Fatigue Impact Scale (MFIS), the Functional Assessment of Chronic Illness Therapy measure system (fatigue version) (FCIT-F), and a new tool for the assessment of fatigue and fatigability: the F-2-MS scale. Internal consistency was estimated with Cronbach's Alpha. For intergroup comparisons, Student's t-test and Pearson's chi-squared test were used. Pearson's correlation test was calculated for quantitative variables. Cohen's d was calculated to evaluate the effect size. Binary logistic regression was performed, considering the presence of fatigue as a criterion variable, and the FACIT-F and F-2-MS scores were added as predictor variables. ROC curves were also estimated. We conducted a confirmatory factor analysis for the F-2-MS scale, considering two latent factors. FACIT-F and F-2-MS showed high internal consistency. Both scales were highly correlated with MFIS and FSS, and showed a low correlation with Symbol Digit Modalities Test. There were significant differences between fatigued and non-fatigued patients on FACIT-F and F-2-MS scores with large effect sizes. Both scales showed AUC > 0.90 and achieved a correct classification >87%. Confirmatory factor analysis showed moderate evidence of two dimensions on the F-2-MS scale. The FACIT-F and F-2-MS scales showed appropriated psychometric properties to be used as fatigue measures in clinical and research settings, allowing a correct distinction between patients with and without fatigue, and contributing to the understanding of the complexities of fatigue in MS.

Sections du résumé

BACKGROUND BACKGROUND
Fatigue is one of the most common symptoms in neurology, especially in MS patients with a prevalence of 65%. It is described as the most disabling symptom by 40% of MS patients. This study aimed to validate the Functional Assessment of Chronic Illness Therapy fatigue version (FACIT-F) and the F-2-MS scale, a new tool to distinguish between fatigue and fatigability.
METHODS METHODS
One hundred and fifteen patients with relapsing-remitting MS were enrolled. All patients completed a comprehensive neuropsychological battery, previously validated in MS. Fatigue was evaluated using the Fatigue Severity Scale (FSS), the Modified version of the Fatigue Impact Scale (MFIS), the Functional Assessment of Chronic Illness Therapy measure system (fatigue version) (FCIT-F), and a new tool for the assessment of fatigue and fatigability: the F-2-MS scale. Internal consistency was estimated with Cronbach's Alpha. For intergroup comparisons, Student's t-test and Pearson's chi-squared test were used. Pearson's correlation test was calculated for quantitative variables. Cohen's d was calculated to evaluate the effect size. Binary logistic regression was performed, considering the presence of fatigue as a criterion variable, and the FACIT-F and F-2-MS scores were added as predictor variables. ROC curves were also estimated. We conducted a confirmatory factor analysis for the F-2-MS scale, considering two latent factors.
RESULTS RESULTS
FACIT-F and F-2-MS showed high internal consistency. Both scales were highly correlated with MFIS and FSS, and showed a low correlation with Symbol Digit Modalities Test. There were significant differences between fatigued and non-fatigued patients on FACIT-F and F-2-MS scores with large effect sizes. Both scales showed AUC > 0.90 and achieved a correct classification >87%. Confirmatory factor analysis showed moderate evidence of two dimensions on the F-2-MS scale.
CONCLUSIONS CONCLUSIONS
The FACIT-F and F-2-MS scales showed appropriated psychometric properties to be used as fatigue measures in clinical and research settings, allowing a correct distinction between patients with and without fatigue, and contributing to the understanding of the complexities of fatigue in MS.

Identifiants

pubmed: 35487033
pii: S2211-0348(22)00338-8
doi: 10.1016/j.msard.2022.103826
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103826

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Alfonso Delgado-Álvarez (A)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Jordi A Matías-Guiu (JA)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain. Electronic address: jordi.matias-guiu@salud.madrid.org.

Cristina Delgado-Alonso (C)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Constanza Cuevas (C)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Marta Palacios-Sarmiento (M)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Lucía Vidorreta-Ballesteros (L)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Paloma Montero-Escribano (P)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Jorge Matías-Guiu (J)

Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC). Universidad Complutense, Profesor Martin Lagos St., Madrid 28040, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH